BYD
6.12.2023 13:07:31 CET | Business Wire | Press release
BYD Ecuador (hereafter referred to as BYD) and the Latin American Energy Organization (OLADE) announced that an Interinstitutional Cooperation Agreement was formalized recently, with the aim of advancing the cause of electric mobility in Latin America and the Caribbean.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231206085642/en/
BYD and OLADE Form Strategic Partnership (Left: Executive Secretary of OLADE, Andrés Rebolledo Smitmans; Right: Country Manager of BYD Ecuador, Jorge Burbano) (Photo: Business Wire)
OLADE, under the leadership of its Executive Secretary, Andrés Rebolledo Smitmans, and BYD, represented by Jorge Burbano, Country Manager of BYD Ecuador, have signed this agreement, solidifying their joint commitment to promoting electric vehicles and accelerating energy transitions in the region.
Established in 1973, OLADE is a respected intergovernmental cooperation organization dedicated to fostering energy integration, development, and conservation in Latin America and the Caribbean. In contrast, BYD, founded in 1995, stands as a leading technology company with a focus on innovation in diverse industries, including automobiles, electronics, rail transit, and new energy.
The collaboration outlined in this agreement will encompass crucial elements such as promoting sustainable mobility, conducting workshops, and providing specialized training in electromobility. These initiatives will target both the public and private sectors, academia, specialized guilds, and civil society in Latin America and the Caribbean. Moreover, the partnership will involve site visits and technical demonstrations at OLADE facilities, specifically focusing on electromobility, for universities, technology centers, educational institutions, guilds, and related organizations. Additionally, BYD’s vehicles will be utilized in OLADE’s electromobility studies, aligning with OLADE’s work plans.
BYD will significantly contribute to this collaboration by providing a TANG EV electric vehicle model along with a charging station. This equipment will be used to demonstrate the electric infrastructure and the vehicle's autonomy, emphasizing the advantages of electric vehicles.
Commenting on the partnership, Jorge Burbano, Country Manager of BYD Ecuador, stated, “We are deeply honored to collaborate with OLADE, leveraging our expertise in electric mobility and energy solutions. Our joint mission is crucial – reducing CO2 emissions and contributing to global efforts to cool the earth by 1℃. I am confident that our cooperation will serve as a beacon for knowledge transfer and research, fostering sustainable development and energy security in the region.”
The Executive Secretary of OLADE, Andrés Rebolledo, highlighted the significance of the recent agreement as a key commitment to regional energy integration and cooperation for the benefit of OLADE’s 27 member countries. He emphasized the importance of transitioning to a sustainable vision in Latin America and the Caribbean, advocating for a long-term perspective in energy integration. This milestone signifies a notable collaboration between both entities, dedicated to a cleaner and more sustainable future for the region. It focuses on priority areas such as electrification of mobility and sustainable mobility training, with the possibility of agreeing on specific agreements for the execution of projects aligned with their shared objectives.
Through this agreement, BYD and OLADE reaffirm their dedication to regional energy integration and cooperation for the benefit of member countries. By closely collaborating and implementing joint projects, they aim to promote sustainable development and optimize energy resources and transportation through clean energy sources in the region.
About BYD
BYD is a multinational high-tech company devoted to leveraging technological innovations for a better life. Founded in 1995 as a rechargeable battery maker, BYD now boasts a diverse business scope covering automobiles, rail transit, new energy, and electronics, with over 30 industrial parks in China, the United States, Canada, Japan, Brazil, Hungary, and India. From energy generation and storage to its applications, BYD is dedicated to providing zero-emission energy solutions that reduce global reliance on fossil fuels. Its new energy vehicle footprint now covers 6 continents, over 70 countries and regions, and more than 400 cities. Listed in both Hong Kong and Shenzhen Stock Exchanges, the company is known to be a Fortune Global 500 enterprise that furnishes innovations in pursuit of a greener world.
For more information, please visit www.bydglobal.com.
About BYD Auto
Founded in 2003, BYD Auto is the automotive subsidiary of BYD, a multinational high-tech company devoted to leveraging technological innovations for a better life. Aiming to accelerate the green transition of the global transportation sector, BYD Auto focuses on developing pure electric and plug-in hybrid vehicles. The company has mastered the core technologies of the entire industrial chain of new energy vehicles, such as batteries, electric motors, electronic controllers, and automotive-grade semiconductors. It has witnessed in recent years significant technological advancements, including the Blade Battery, DM-i Super Hybrid Technology, e Platform 3.0, CTB Technology, e4 Platform, BYD DiSus Intelligent Body Control System, and DMO super hybrid system. The company is the world’s first carmaker to stop the production of fossil-fueled vehicles on EV shift and has remained top of new energy passenger vehicle sales in China for 10 years in a row.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231206085642/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom